Interpatient variability in tamoxifen respone among breast cancer patient: the use of pharmacogenetics and metabolomics in closing the gaps in clinical practice
Tamoxifen has been widely used as the standard adjuvant therapy for breast cancer patients with oestrogen receptor-positive status, especially in the high-risk pre- and postmenopausal women. However, 30 to 50% of ER-positive breast cancer patients do not respond to tamoxifen therapy. Major challenge...
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2017
|
| Subjects: | |
| Online Access: | https://ir.uitm.edu.my/id/eprint/121423/1/121423.pdf |
| Abstract | Abstract here |